Recent blog posts
AltruBio declares FDA approval on IND submission for ALTB-268, an Immune Checkpoint Booster, triggering a Phase 2 Clinical Study for dealing with Ulcerative Colitis
Latest Hotspot
3 min read
AltruBio declares FDA approval on IND submission for ALTB-268, an Immune Checkpoint Booster, triggering a Phase 2 Clinical Study for dealing with Ulcerative Colitis
8 October 2023
The US FDA approved AltruBio Inc.'s IND request, allowing Phase 2 clinical trials to start for its immune checkpoint booster, ALTB-268, for ulcerative colitis.
Read →
Alfasigma set to purchase Intercept Pharmaceuticals at $19.00 each stock in cash, broadening international reach in unusual and critical liver ailments
Latest Hotspot
3 min read
Alfasigma set to purchase Intercept Pharmaceuticals at $19.00 each stock in cash, broadening international reach in unusual and critical liver ailments
8 October 2023
Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.
Read →
Gracell Biotechnologies starts dosing in US Phase 1b/2 trial assessing GC012F's efficacy for treating recurrent or resistant multiple myeloma
Latest Hotspot
3 min read
Gracell Biotechnologies starts dosing in US Phase 1b/2 trial assessing GC012F's efficacy for treating recurrent or resistant multiple myeloma
8 October 2023
Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.
Read →
Adverum Biotechnologies reported encouraging Aflibercept Protein level results from their LUNA Phase 2 study
Latest Hotspot
3 min read
Adverum Biotechnologies reported encouraging Aflibercept Protein level results from their LUNA Phase 2 study
7 October 2023
Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.
Read →
Smart Immune begins administering its ProTcell Therapy SMART101 to leukemia patients in the ReSET-02 Phase I/II study
Latest Hotspot
3 min read
Smart Immune begins administering its ProTcell Therapy SMART101 to leukemia patients in the ReSET-02 Phase I/II study
5 October 2023
Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.
Read →
Ionis reports positive early results from Phase 3 trial of Olezarsen for familial chylomicronemia syndrome patients
Latest Hotspot
3 min read
Ionis reports positive early results from Phase 3 trial of Olezarsen for familial chylomicronemia syndrome patients
5 October 2023
Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.
Read →
YS Biopharma Initiates Patient Registration for Key Phase 3 Study on PIKA Rabies Vaccine
Latest Hotspot
3 min read
YS Biopharma Initiates Patient Registration for Key Phase 3 Study on PIKA Rabies Vaccine
5 October 2023
YS Biopharma Co., Ltd., pledged to discovery, develop, produce, and supply innovative vaccines and therapeutic biologics for infectious illnesses and cancer.
Read →
Remegen's new drug Telitacicept (RC18) yields positive Phase III results, applies for additional use in treating rheumatoid arthritis
Latest Hotspot
3 min read
Remegen's new drug Telitacicept (RC18) yields positive Phase III results, applies for additional use in treating rheumatoid arthritis
5 October 2023
Remegen's Novel Medication Telitacicept (RC18) Achieves Favorable Phase III Outcomes, Applied for a Secondary Use in Managing Rheumatoid Arthritis.
Read →
Mesentech Begins Administering Experimental Medicine MES1022 to Speed Up Bone Fracture Recovery in Initial Patients
Latest Hotspot
4 min read
Mesentech Begins Administering Experimental Medicine MES1022 to Speed Up Bone Fracture Recovery in Initial Patients
4 October 2023
Mesentech recently revealed that its Phase 1 trial has begun, and the initial patients have already received their doses of MES1022.
Read →
Elpiscience initiates Phase 1 clinical trial of Anti-LILRB2 Antibody ES009 with first patient dosed in Australia
Latest Hotspot
3 min read
Elpiscience initiates Phase 1 clinical trial of Anti-LILRB2 Antibody ES009 with first patient dosed in Australia
4 October 2023
Elpiscience Biopharmaceuticals has revealed that the initial patient has received a dose in a Phase 1 clinical study of the anti-LILRB2 monoclonal antibody ES009 in Australia.
Read →
Edgewise Therapeutics Launches Worldwide Crucial Trial of EDG-5506 for Becker Muscular Dystrophy, Called GRAND CANYON
Latest Hotspot
3 min read
Edgewise Therapeutics Launches Worldwide Crucial Trial of EDG-5506 for Becker Muscular Dystrophy, Called GRAND CANYON
3 October 2023
Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.
Read →
Arcturus Therapeutics and the Cystic Fibrosis Foundation are collaborating on the production of ARCT-032, a possible mRNA treatment for Cystic Fibrosis
Latest Hotspot
3 min read
Arcturus Therapeutics and the Cystic Fibrosis Foundation are collaborating on the production of ARCT-032, a possible mRNA treatment for Cystic Fibrosis
3 October 2023
Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.
Read →